The Relationships of Vitamin D, Vitamin D Receptor Gene Polymorphisms, and Vitamin D Supplementation with Parkinson's Disease

Overview

Journal Transl Neurodegener

Publisher Biomed Central

Date 2020 Sep 2

PMID 32867847

Citations 24

Authors

Lingling Lv

Xuling Tan

Xinke Peng

Rongrong Bai

Qile Xiao

Ting Zou

Jieqiong Tan

Hainan Zhang

Chunyu Wang

Affiliations

Soon will be listed here.

Abstract

In recent years, many studies have investigated the correlations between Parkinson's disease (PD) and vitamin D status, but the conclusion remains elusive. The present review focuses on the associations between PD and serum vitamin D levels by reviewing studies on the associations of PD with serum vitamin D levels and vitamin D receptor (VDR) gene polymorphisms from PubMed, Web of Science, Cochrane Library, and Embase databases. We found that PD patients have lower vitamin D levels than healthy controls and that the vitamin D concentrations are negatively correlated with PD risk and severity. Furthermore, higher vitamin D concentrations are linked to better cognitive function and mood in PD patients. Findings on the relationship between VDR gene polymorphisms and the risk of PD are inconsistent, but the FokI (C/T) polymorphism is significantly linked with PD. The occurrence of FokI (C/T) gene polymorphism may influence the risk, severity, and cognitive ability of PD patients, while also possibly influencing the effect of Vitamin D supplementation in PD patients. In view of the neuroprotective effects of vitamin D and the close association between vitamin D and dopaminergic neurotransmission, interventional prospective studies on vitamin D supplementation in PD patients should be conducted in the future.

Citing Articles

Association of 25-hydroxyvitamin D with Parkinson's disease based on the results from the NHANES 2007 to 2018 and Mendelian randomization analysis.

Xu Y, Peng J, Zhou X, Huang Y, Zhong G, Xia Z Sci Rep. 2025; 15(1):5514.

PMID: 39953081 PMC: 11828982. DOI: 10.1038/s41598-025-87120-6.

Integrating network pharmacology with molecular docking and dynamics to uncover therapeutic targets and signaling mechanisms of vitamin D3 in Parkinson's disease.

Wang C, Wang Y, Xu Q Mol Divers. 2025; .

PMID: 39821175 DOI: 10.1007/s11030-024-11090-6.

Vitamin D and focal brain atrophy in PD with non-dementia: a VBM study.

Xu Y, Wang E, Zhang Q, Liu J, Luo W Front Hum Neurosci. 2024; 18:1474148.

PMID: 39677405 PMC: 11638236. DOI: 10.3389/fnhum.2024.1474148.

SARS-CoV-2 induced vitamin D deficiency and psychological stress: a manifestation of autoimmune disease onset.

Alobaid M, Alqabandi B Front Immunol. 2024; 15:1434486.

PMID: 39416791 PMC: 11479920. DOI: 10.3389/fimmu.2024.1434486.

VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson's disease.

Zheng Z, Chen M, Feng S, Zhao H, Qu T, Zhao X Cell Death Discov. 2024; 10(1):150.

PMID: 38514643 PMC: 10957901. DOI: 10.1038/s41420-024-01912-9.

References

Armstrong M, Okun M . Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020; 323(6):548-560. DOI: 10.1001/jama.2019.22360. View

Balden R, Selvamani A, Sohrabji F . Vitamin D deficiency exacerbates experimental stroke injury and dysregulates ischemia-induced inflammation in adult rats. Endocrinology. 2012; 153(5):2420-35. PMC: 3339639. DOI: 10.1210/en.2011-1783. View

Hornykiewicz O . The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl. 2006; (70):9-15. DOI: 10.1007/978-3-211-45295-0_3. View

Selvaraj S, Sun Y, Watt J, Wang S, Lei S, Birnbaumer L . Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest. 2012; 122(4):1354-67. PMC: 3314472. DOI: 10.1172/JCI61332. View

Lee C, Choi S, Shin D, Yi S, Kim K, Kim I . Parkinson's disease and the risk of osteoporotic vertebral compression fracture: a nationwide population-based study. Osteoporos Int. 2018; 29(5):1117-1124. DOI: 10.1007/s00198-018-4409-9. View

Zhu D, Liu G, Lv Z, Wen S, Bi S, Wang W . Inverse associations of outdoor activity and vitamin D intake with the risk of Parkinson's disease. J Zhejiang Univ Sci B. 2014; 15(10):923-7. PMC: 4201321. DOI: 10.1631/jzus.B1400005. View

Tanaka K, Miyake Y, Fukushima W, Kiyohara C, Sasaki S, Tsuboi Y . Vitamin D receptor gene polymorphisms, smoking, and risk of sporadic Parkinson's disease in Japan. Neurosci Lett. 2017; 643:97-102. DOI: 10.1016/j.neulet.2017.02.037. View

Scherzer C, Eklund A, Morse L, Liao Z, Locascio J, Fefer D . Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007; 104(3):955-60. PMC: 1766335. DOI: 10.1073/pnas.0610204104. View

Smith M, Fletcher-Turner A, Yurek D, Cass W . Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res. 2006; 31(4):533-9. DOI: 10.1007/s11064-006-9048-4. View

10.

Feart C, Helmer C, Merle B, Herrmann F, Annweiler C, Dartigues J . Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer's disease in older adults. Alzheimers Dement. 2017; 13(11):1207-1216. DOI: 10.1016/j.jalz.2017.03.003. View

11.

Eyles D, Burne T, McGrath J . Vitamin D in fetal brain development. Semin Cell Dev Biol. 2011; 22(6):629-36. DOI: 10.1016/j.semcdb.2011.05.004. View

12.

Uitterlinden A, Fang Y, van Meurs J, van Leeuwen H, Pols H . Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):187-93. DOI: 10.1016/j.jsbmb.2004.03.083. View

13.

Grillo C, DAmbrosio C, Scaloni A, Maceroni M, Merluzzi S, Turano C . Cooperative activity of Ref-1/APE and ERp57 in reductive activation of transcription factors. Free Radic Biol Med. 2006; 41(7):1113-23. DOI: 10.1016/j.freeradbiomed.2006.06.016. View

14.

Sato Y, Kikuyama M, Oizumi K . High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology. 1997; 49(5):1273-8. DOI: 10.1212/wnl.49.5.1273. View

15.

Chitsaz A, Maracy M, Basiri K, Izadi Boroujeni M, Tanhaei A, Rahimi M . 25-hydroxyvitamin d and severity of Parkinson's disease. Int J Endocrinol. 2013; 2013:689149. PMC: 3730208. DOI: 10.1155/2013/689149. View

16.

Berridge M . Vitamin D cell signalling in health and disease. Biochem Biophys Res Commun. 2015; 460(1):53-71. DOI: 10.1016/j.bbrc.2015.01.008. View

17.

Weissmiller A, Wu C . Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012; 1(1):14. PMC: 3542569. DOI: 10.1186/2047-9158-1-14. View

18.

Uitterlinden A, Fang Y, van Meurs J, Pols H, van Leeuwen J . Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004; 338(2):143-56. DOI: 10.1016/j.gene.2004.05.014. View

19.

Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Kawasaki K, Noya M . 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Mov Disord. 2012; 27(2):264-71. DOI: 10.1002/mds.24016. View

20.

Ross A, Manson J, Abrams S, Aloia J, Brannon P, Clinton S . The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2010; 96(1):53-8. PMC: 3046611. DOI: 10.1210/jc.2010-2704. View